Dr. Dugan joined Dracen Pharmaceuticals in 2018 with 20 + years of experience as a senior leader, more recently as Senior Vice-President, in Novartis oncology global strategic drug development and portfolio management, including translational science, early and late clinical development, life cycle management and companion diagnostic development that resulted in several regulatory filings and approvals (Femara® and Ceritinib), including Breakthrough Therapy Designations. Direct experience with global health authorities including FDA, EMA and PMDA and national authorities. She led the Novartis Exploratory Oncology Development Group for five years which transitioned compounds from discovery to proof-of-concept in the clinic, including Tasigna. Dr. Dugan also held several development positions at Schering-Plough (now Merck & Co.), which led to the first approval of temozolomide for brain tumors and American Cyanamid (now Pfizer). Dr. Dugan received her BA and medical degrees and training in hematology and oncology from New York University.